<DOC>
	<DOCNO>NCT00474110</DOCNO>
	<brief_summary>The treatment cancer child may result extremely painful condition call oral mucositis cell line mouth injured due cancer medication . Patients condition often unable take anything mouth swallow saliva . This severe pain may last long 2 week . A survey previous 22 patient show high daily pain score despite use intravenous ( give small tube vein ) opioid medication ( family pain relieve drug , e.g . morphine hydromorphone ) . The purpose pilot study determine 3 concentration ketamine combine hydromorphone provide best pain relief minimum side effect . The result study allow u large study compare best concentration find study standard treatment . If successful , combination ketamine hydromorphone also use treat pain problem child .</brief_summary>
	<brief_title>Ketamine Hydromorphone Patient Controlled Pain Relief Children 's Mucositis</brief_title>
	<detailed_description>The purpose observational pilot study evaluate feasibility , efficacy optimum ratio compound mixture HM-K administer parenterally PCA pediatric mucositis patient inadequate analgesia use conventional HM PCA . An open-label study 20 consecutive consenting/assenting subject meet study criterion conduct . All patient eligible study approach inform , write consent subject age 7 complete assent form . The subject examine pediatric oncology fellow/staff determine level clinical severity mucositis use Oral Mucositis Assessment Scale ( OMAS ) World Health Organization Mucositis Scale . A modify Colour Analogue Scale ( mCAS ) originally design evaluate pain intensity use evaluate self-report symptom . The subject receive 24 hour therapy use compound HM-K PCA solution . Initial PCA prescription Background Bolus set exist setting morning recruitment per study entry criterion minimum hourly use 4 mcg/kg/hour HM . The 1-hour Maximum set 4 time Background dose . At 24 hour , 24-hour HM K consumption calculate . The subject re-examined pediatric oncology fellow/staff determine level clinical severity mucositis self-report symptom evaluation questionnaire administer . Conventional Therapy HM PCA restart 24 hour , mucositis severity self-report symptom evaluation questionnaire administer . Descriptive summary demographic data provide . The 24-hour HM utilization compare study entry-level utilization ( 24 hour period prior recruitment ) . A 30 % reduction opioid use consider clinically important.A Symptom Index Start Study Symptom Level - End Study Symptom Level / Start Study Symptom level calculate symptom include pain intensity . An Index great equal 0.5 consider positive outcome . Indexes 0 , 24 48 hour compare . A descriptive summary incidence treatment opioid-induced side effect 0 , 24 48 hour provide . Ketamine Solution Concentrations Solution 1 ( low ) : HM 0.2 K 0.2 mg/mL ( 1:1 ) - 20 mg/20 mg 100 mL . Solution 2 ( medium ) : HM 0.2 K 0.6 mg/mL ( 1:3 ) - 20 mg/60 mg 100 mL . Solution 3 ( high ) : HM 0.2 K 1 mg/mL ( 1:5 ) - 20 mg/100 mg 100 mL . The start solution Solution 2 minimum dose 4 mcg/kg/hour hydromorphone ( HM ) 12 mcg/kg/hour ketamine ( K ) ( 0.02 mL/kg/hour solution . `` Add background '' : 4 mcg/kg/hour Hydromorphone equivalent ( 0.02 mL/kg/hour solution ) may occur required solution change criterion meet . `` Increase background '' : additional 4 mcg/kg/hour Hydromorphone equivalent ( 0.02 mL/kg/hour solution ) . Repeat `` Increase background '' : 4 mcg/kg/hour Hydromorphone equivalent ( 0.02 mL/kg/hour solution ) may occur 3 hourly required solution change criterion meet . `` Decrease background '' : decrease 4 mcg/kg/hour Hydromorphone equivalent ( 0.02 mL/kg/hour solution ) may occur 3 hourly required solution change criterion meet . `` Stop background '' : Background stop bolus dose remains . May occur background reduce 4 mcg/kg/hour Hydromorphone least 3 hour exceessive ADEs . `` D/C background : Discontinue background HM bolus remain . `` Stop Study ( SS ) '' : Converting PCA conventional HM therapy adjuvant require accord exist practice Acute Pain Service . For compassionate reason , patient/family express remain STudy Therapy , accept . Once patient ADEs require Solution 1 , may re-start solution 2 3 .</detailed_description>
	<mesh_term>Mucositis</mesh_term>
	<mesh_term>Ketamine</mesh_term>
	<mesh_term>Hydromorphone</mesh_term>
	<criteria>Pediatric oral mucositis due antineoplastic therapy . Must receive concurrent oral analgesic sedative acetaminophen , gabapentin , lorazepam , nabilone clonidine .</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>19 Years</maximum_age>
	<verification_date>October 2010</verification_date>
	<keyword>Ketamine</keyword>
	<keyword>hydromorphone</keyword>
	<keyword>pediatric mucositis</keyword>
</DOC>